Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load [1]

Lancet

Volumn 349, Issue 9064, 1997, Pages 1517-

  Rübsamen Waigmann, Helga ^a   Huguenel, Edward ^b,c,d   Paessens, Arno ^b,c,d   Kleim, Jörg Peter ^b,c,d   Wainbeig, Mark A ^b,c,d   Shah, Anita ^b,c,d  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

^c General Pharma Research   (Germany)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; ZIDOVUDINE;

CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG PROTEIN BINDING; DRUG RESISTANCE; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

EID: 0343852696     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)24021-3     Document Type: Article

References (5)

1. Myers MW, Montaner JG. A randomized double-blinded comparative trial of the effects of zidovudine didanosine and nevirapine combinations in antiviral naive AIDS-free, HIV-infected patients with CD4 counts 200-600/MM3, XI Int. Conf. on AIDS/Vancouver 1996, Abstr. Mo.B.294.
2. Staszewski S, Massari FE, Kober A, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistant to L-697, 661 a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995; 171: 1159-65.
3. Kleim JP, Bender R, Kirsch R, et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1995; 39: 2253-57.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
5. Mayers D, Riddler S, Stein D, et al. A double blind pilot study to evaluate the antiviral activity, tolerability and pharmakokinetics of DMP 266 alone and in combination with Indinavir, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 15.-18.09.1996.